OMNICELL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.59 USD | -0.18% |
|
-0.12% | -13.39% |
| May. 16 | Transcript : Omnicell, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM | |
| May. 02 | Omnicell Shares Rise After Q1 Non-GAAP Earnings, Revenue Beat Estimates | MT |
Financials (USD)
| Sales 2024 * | 1.07B | Sales 2025 * | 1.14B | Capitalization | 1.5B |
|---|---|---|---|---|---|
| Net income 2024 * | -11M | Net income 2025 * | 18M | EV / Sales 2024 * | 1.42 x |
| Net Debt 2024 * | 22.15M | Net cash position 2025 * | 50.92M | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
-130
x | P/E ratio 2025 * |
129
x | Employees | 3,590 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Omnicell, Inc.
More recommendations
More press releases
More news
| 1 day | -0.18% | ||
| 1 week | -0.12% | ||
| 1 month | +21.56% | ||
| 3 months | +24.20% | ||
| 6 months | -2.31% | ||
| Current year | -13.39% |
1 week
31.42
33.38
1 month
26.8933.38
Current year
25.6938.15
1 year
25.6977.14
3 years
25.69187.29
5 years
25.69187.29
10 years
25.06187.29
| Managers | Title | Age | Since |
|---|---|---|---|
Randall Lipps
CEO | Chief Executive Officer | 66 | 92-08-31 |
Nchacha Etta
DFI | Director of Finance/CFO | - | 23-05-31 |
Corey Manley
ADM | Chief Administrative Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Parrish
BRD | Director/Board Member | 68 | 12-12-31 |
Joanne Bauer
BRD | Director/Board Member | 68 | 13-12-31 |
Randall Lipps
CEO | Chief Executive Officer | 66 | 92-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.46% | 144 M€ | -0.99% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 32.59 | -0.18% | 315,341 |
| 24-05-30 | 32.65 | +2.64% | 297,423 |
| 24-05-29 | 31.81 | -1.82% | 319,965 |
| 24-05-28 | 32.4 | -0.70% | 263,131 |
| 24-05-24 | 32.63 | +2.93% | 475,305 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
32.59
USD
Average target price
33.14
USD
Spread / Average Target
+1.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.39% | 1.5B | |
| -9.49% | 28.16B | |
| +25.35% | 8.33B | |
| +33.25% | 4.39B | |
| -35.85% | 2.43B | |
| -9.44% | 1.6B | |
| -32.84% | 1.15B | |
| +7.80% | 964M | |
| -37.56% | 872M | |
| -20.77% | 700M |
- Stock Market
- Equities
- OMCL Stock
